XBI Quote, Financials, Valuation and Earnings

Fidelity MSCI Health Care Index ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Fidelity MSCI Health Care Index ETF's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity MSCI Health Care Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Fidelity MSCI Health Care Index ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Fidelity MSCI Health Care Index ETF.

SPDR S&P Biotech ETF has a beta of 0.919, which suggesting that the stock is 8.063% less volatile than S&P 500. In comparison Fidelity MSCI Health Care Index ETF has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.505%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.04%. Fidelity MSCI Health Care Index ETF offers a yield of 1.6% to investors and pays a quarterly dividend of $0.26 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Fidelity MSCI Health Care Index ETF pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Fidelity MSCI Health Care Index ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Fidelity MSCI Health Care Index ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Fidelity MSCI Health Care Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Fidelity MSCI Health Care Index ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Invesco Biotechnology & Genome ETF.

SPDR S&P Biotech ETF has a beta of 0.919, which suggesting that the stock is 8.063% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.809, suggesting its less volatile than the S&P 500 by 19.078%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.04%. Invesco Biotechnology & Genome ETF offers a yield of 0.26% to investors and pays a quarterly dividend of $0.13 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.

SPDR S&P Health Care Equipment ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe SPDR S&P Biotech ETF is more attractive than SPDR S&P Health Care Equipment ETF.

SPDR S&P Biotech ETF has a beta of 0.919, which suggesting that the stock is 8.063% less volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.055, suggesting its more volatile than the S&P 500 by 5.483%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.04%. SPDR S&P Health Care Equipment ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.02 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.

Health Care Select Sector SPDR Fund has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Health Care Select Sector SPDR Fund's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Health Care Select Sector SPDR Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Health Care Select Sector SPDR Fund, analysts believe SPDR S&P Biotech ETF is more attractive than Health Care Select Sector SPDR Fund.

SPDR S&P Biotech ETF has a beta of 0.919, which suggesting that the stock is 8.063% less volatile than S&P 500. In comparison Health Care Select Sector SPDR Fund has a beta of 0.654, suggesting its less volatile than the S&P 500 by 34.588%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.04%. Health Care Select Sector SPDR Fund offers a yield of 1.79% to investors and pays a quarterly dividend of $0.63 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Health Care Select Sector SPDR Fund pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Health Care Select Sector SPDR Fund quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Health Care Select Sector SPDR Fund's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Health Care Select Sector SPDR Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Health Care Select Sector SPDR Fund. Usually stocks with elevated PS ratios are considered overvalued.